Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 1989 / Article

Review | Open Access

Volume 3 |Article ID 768562 | https://doi.org/10.1155/1989/768562

M. Campieri, P. Gionchetti, A. Belluzzi, C. Brignola, P. Iannone, M. Miglioli, L. Barbara, "Therapy of Inflammatory Bowel Disease using 5-Aminosalicylic Acid, 4-Aminosalicylic Acid and Olsalazine Retention Enemas: Review of Clinical Trials", Canadian Journal of Gastroenterology and Hepatology, vol. 3, Article ID 768562, 3 pages, 1989. https://doi.org/10.1155/1989/768562

Therapy of Inflammatory Bowel Disease using 5-Aminosalicylic Acid, 4-Aminosalicylic Acid and Olsalazine Retention Enemas: Review of Clinical Trials

Abstract

The knowledge that 5-aminosalicylic acid (5-ASA) is the active compound of sulphasalazine and that it acts topically has stimulated the use of 5-ASA containing enemas and ocher similar compounds such as olsalazine and 4-aminosalicylic acid (4-ASA). 5-ASA enemas have been shown to be effective in controlling active disease in clinical trials and have also been shown to be of benefit in prevention of relapses. Olsalazine enemas have not demonstrated significantly better results than placebo 4-ASA enemas are effective but the results obtained have differed as to effective dose

Copyright © 1989 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views45
Downloads116
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.